Australia markets close in 4 hours 18 minutes
  • ALL ORDS

    7,134.80
    +20.30 (+0.29%)
     
  • ASX 200

    6,859.10
    +20.80 (+0.30%)
     
  • AUD/USD

    0.7033
    -0.0000 (-0.01%)
     
  • OIL

    87.21
    +0.60 (+0.69%)
     
  • GOLD

    1,795.00
    +1.90 (+0.11%)
     
  • BTC-AUD

    52,840.02
    -177.42 (-0.33%)
     
  • CMC Crypto 200

    840.37
    +20.87 (+2.55%)
     
  • AUD/EUR

    0.6308
    -0.0000 (-0.00%)
     
  • AUD/NZD

    1.0699
    +0.0018 (+0.17%)
     
  • NZX 50

    11,951.54
    -98.78 (-0.82%)
     
  • NASDAQ

    14,003.11
    -169.65 (-1.20%)
     
  • FTSE

    7,554.31
    +84.53 (+1.13%)
     
  • Dow Jones

    34,160.78
    -7.31 (-0.02%)
     
  • DAX

    15,524.27
    +64.88 (+0.42%)
     
  • Hang Seng

    23,807.00
    -482.90 (-1.99%)
     
  • NIKKEI 225

    26,403.18
    +232.88 (+0.89%)
     

Global Rheumatoid Arthritis Market – Analysis By Drug Type, Treatment, Diagnosis, By Region, By Country: Market Insights and Forecast with Impact of COVID-19

·2-min read

Executive Summary The Global Rheumatoid Arthritis Market was valued at USD 24. 46 Billion in the year 2020. Globally, the market for rheumatoid arthritis is increasing rapidly and the major factor that drives the growth of rheumatoid arthritis is the increasing ageing population.

New York, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Rheumatoid Arthritis Market – Analysis By Drug Type, Treatment, Diagnosis, By Region, By Country: Market Insights and Forecast with Impact of COVID-19" - https://www.reportlinker.com/p06187379/?utm_source=GNW
Furthermore, some evidence suggests that people who smoke are at an increased risk of developing rheumatoid arthritis.

DMARDs segment is expected to hold a significant share in the Rheumatoid Arthritis Market on the back of the increasing prevalence of rheumatoid arthritis incidences across the globe, the launch of the therapeutic agents, and the favourable reimbursement policies for the high-cost treatment products. These are the major factors propelling the growth of the market.

Americas region dominated the global Rheumatoid Arthritis market and led the industry in 2020 owing to the presence of a large patient base and availability of well-developed infrastructure, rising awareness regarding disease treatment, growing geriatric population, and high adoption of biopharmaceuticals for treatment.

There is also an increase in funds provided to academic research institutions and individual researchers that is expected to boost the market growth. Moreover, various initiatives by international bodies, such as WHO and NIH for the prevention and treatment of chronic disorders, such as cardiovascular diseases, Rheumatoid Arthritis and cancer are anticipated to facilitate the growth of the market.

Scope of the Report
• The report presents the analysis of the Rheumatoid Arthritis market for the historical period of 2016-2020 and the forecast period of 2021-2026.

• The report analyses the Rheumatoid Arthritis Market by Value (USD Million).

• The report analyses the Rheumatoid Arthritis Market By Drug Type – NSAID(non-steroidal anti-inflammatory drugs), DMARDs (Disease-modifying anti-rheumatic drug), Corticosteroids, Others

• The report analyses the Rheumatoid Arthritis Market by Treatment – Tendon Repair, Joint Fusion, Joint Replacement, Others.

• The report analyses the Rheumatoid Arthritis Market By Diagnosis – CRP (Creative Protein Test), ESR (Erythrocyte Sedimentation Rate), Others.

• The Global Rheumatoid Arthritis Market has been analysed by countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India).

• Also, the attractiveness of the market has been presented by region, by Drug Type, by Treatment, By Diagnosis.

• Also, the major opportunities, trends, drivers and challenges of the industry have been analysed in the report.

• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include Merck KGaA, Sanofi, Eli Lilly Company, Amgen Inc., Bristol-Mayor Squibb, F. Hoffman-La Roche Ltd., Johnson & Johnson, Cipla, Pfizer, Galapagos NV, Gilead Sciences.

Key Target Audience

• Pharmaceutical Companies

• Consulting and Advisory Firms

• Government and Policy Makers

• Regulatory Authorities
Read the full report: https://www.reportlinker.com/p06187379/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting